Combination therapeutics for the world's toughest diseases
Olio labs uses AI to develop combination therapeutics that consider the thousands of interacting proteins in your body rather than targeting just one or two. Their lead combinations target obesity and are more effective with fewer side effects than Ozempic, the fastest growing drug of all time. Their custom ML built from real-world expertise and cutting edge AI searches trillions of combinations to find the perfect one.
Active Founders
David Tingley
David has over 13 years of experience as a systems neuroscientist and biologist. His interest in systems biology led him to earn a PhD in Neuroscience at New York University and complete postdoctoral research at Harvard. During this time, he published more than 15 scientific articles and uncovered a link between oscillations in brain activity and glucose metabolism in the body (Tingley et al., Nature 2020).
Tom Roseberry
Tom has over 15 years of industry experience leading teams and engineering technologies in aerospace, brain machine interfacing, synthetic biology and drug discovery/development. At Neuralink he built and co-led a group that developed a next-generation neural interface. At Loyal he built and led multiple teams as VP of Engineering, Computational Biology and Drug Development.
Company Launches
In short
Olio labs uses AI to develop combination therapeutics that consider the thousands of interacting proteins in your body rather than targeting just one or two.
The problem
Drug discovery focuses on finding therapeutics that target one or two proteins. But proteins are found in many organs throughout the body, which results in side effects.
Combinations of therapeutics allow for better targeting in the right places.
Optimizing a combination requires testing trillions of combinations, which is impossible in vitro (cell culture) or in vivo (rodents).
Solution
We have developed a computational platform that allows rapid in silico testing to find only the most promising combinations to move forward.
We have lead combinations that beat the currently available market-leading drugs.
Who are we?
David and Tom are both systems neuroscientists and worked together on the Computational Biology team at Loyal for Dogs.
In our PhDs we used research tools that allowed single neurons to be turned on or off in order to test their function. These tools are not available in humans, but is there another way to be this precise? Combinations of therapeutics make it possible.
We are a new type of scientist that has emerged over the past decade - as comfortable working at the bench as we are in the codebase. This means we have a full understanding of the problems and tools, from cell to model, with no disconnect between engineers and scientists. We are looking to automate every aspect of the drug discovery and development process and expand our platform into multiple indications.
Get in touch with us if you can help us find:
- Connections in mid to large pharmaceutical companies.
- Leads on any developing molecules you find interesting that we can test out in our models.
- Builders in the AI x Bio space who might resonate with our mission.
… or if you just want to learn more!